Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 21, 2012 - Issue 7
Submit an article Journal homepage
1,289
Views
24
CrossRef citations to date
0
Altmetric
Reviews

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

Kris VaddiIncyte Corp., Pharmacology & Toxicology, Experimental Station, Wilmignton, DE 19880, [email protected]
, PhD &
Monica LuchiIncyte Corp., Inflammatory Disease Development, Experimental Station, Wilmington, DE 19880, USA
, MD
Pages 961-973 | Published online: 22 May 2012

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Xinyu Ge, Sheng Ma, Shu Yan, Yali Wu, Chong Chen, Chongzhuang Tang, Yan Zhan, Yi-cong Bian, Kai Shen, Sheng Feng, Xuehu Gao, Dafang Zhong, Hua Zhang, Li-yan Miao & Xing-xing Diao. (2023) Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans. Xenobiotica 53:2, pages 69-83.
Read now
Hasan Tahir, Swetha Byravan, Armin Fardanesh & Arumugam Moorthy. (2021) Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. Journal of Experimental Pharmacology 13, pages 627-635.
Read now
Christophe Richez, Marie-Elise Truchetet, Marie Kostine, Thierry Schaeverbeke & Bernard Bannwarth. (2017) Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy 18:13, pages 1399-1407.
Read now
Karen Wai, Lisa Marie Saldanha, Elvira Zenaida Lansang, Saumya Nayak, Anish Sule & Ken J Lee. (2013) Case series of feasibility considerations that impact operational delivery strategy in the highly competitive rheumatoid arthritis space in Asia. Open Access Journal of Clinical Trials 5, pages 33-38.
Read now
Bernard Bannwarth, Marie Kostine & Nicolas Poursac. (2013) A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opinion on Drug Metabolism & Toxicology 9:6, pages 753-761.
Read now

Articles from other publishers (19)

Pooja Mathur, Ravinder Verma, Manish Kumar, Vikas Jhawat, Rohit Dutt & Shailendra Bhatt. (2023) Current Remedial Strategies for the Treatment of Rheumatoid Arthritis through the Oral Route with Janus Kinase Inhibitors. Drug Delivery Letters 13:1, pages 13-23.
Crossref
Junying Pan, Haoyu Wang & Yinghua Chen. (2022) Trends and frontiers in natural products for arthritis, 2000–2021: A bibliometric analysis. Medicine 101:45, pages e30996.
Crossref
Xiaofeng Zeng, Dongbao Zhao, Sebastiao C. Radominski, Mauro Keiserman, Chang K. Lee, Sebastian Meerwein, Jeffrey Enejosa, Yunxia Sui, Mohamed‐Eslam F. Mohamed & Won Park. (2021) Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. International Journal of Rheumatic Diseases 24:12, pages 1530-1539.
Crossref
Vijayabhaskar Veeravalli, Ranjeet P. Dash, Jennifer A. Thomas, R. Jayachandra Babu, Lakshmi Mohan Vamsi Madgula & Nuggehally R. Srinivas. (2020) Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety 43:8, pages 711-725.
Crossref
Mohamed‐Eslam F. Mohamed, Denise Beck, Heidi S. Camp & Ahmed A. Othman. (2019) Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. The Journal of Clinical Pharmacology 60:2, pages 188-197.
Crossref
Yosra Bedoui, Xavier Guillot, Jimmy Sélambarom, Pascale Guiraud, Claude Giry, Marie Christine Jaffar-Bandjee, Stéphane Ralandison & Philippe Gasque. (2019) Methotrexate an Old Drug with New Tricks. International Journal of Molecular Sciences 20:20, pages 5023.
Crossref
Kirtikumar D. Bharwad, Priyanka A. Shah, Pranav S. Shrivastav & Puran Singhal. (2019) Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma. Biomedical Chromatography 33:4, pages e4458.
Crossref
Juryun Kim, Yena Kim, Jinhyeok Choi, Hyerin Jung, Kijun Lee, Jaewoo Kang, Narae Park, Yeri Alice Rim, Yoojun Nam & Ji Hyeon Ju. (2018) Recapitulation of methotrexate hepatotoxicity with induced pluripotent stem cell-derived hepatocytes from patients with rheumatoid arthritis. Stem Cell Research & Therapy 9:1.
Crossref
Hasan Tahir. (2018) Therapies in ankylosing spondylitis—from clinical trials to clinical practice. Rheumatology 57:suppl_6, pages vi23-vi28.
Crossref
Philip M. Preshaw. (2017) Host modulation therapy with anti‐inflammatory agents. Periodontology 2000 76:1, pages 131-149.
Crossref
Mohamed-Eslam F. Mohamed, Heidi S. Camp, Ping Jiang, Robert J. Padley, Armen Asatryan & Ahmed A. Othman. (2016) Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. Clinical Pharmacokinetics 55:12, pages 1547-1558.
Crossref
Shaowa Lü, Qiushi Wang, Guoyu Li, Shuang Sun, Yuyan Guo & Haixue Kuang. (2015) The treatment of rheumatoid arthritis using Chinese medicinal plants: From pharmacology to potential molecular mechanisms. Journal of Ethnopharmacology 176, pages 177-206.
Crossref
Mahendra Kumar Verma & Kota Sobha. (2015) Understanding the major risk factors in the beginning and the progression of rheumatoid arthritis: current scenario and future prospects. Inflammation Research 64:9, pages 647-659.
Crossref
Florence Namour, Paul Matthias Diderichsen, Eugène Cox, Béatrice Vayssière, Annegret Van der Aa, Chantal Tasset & Gerben Van‘t Klooster. (2015) Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clinical Pharmacokinetics 54:8, pages 859-874.
Crossref
Wenhua Lv, Qiuyu Wang, He Chen, Yongshuai Jiang, Jiajia Zheng, Miao Shi, Yanjun Xu, Junwei Han, Chunquan Li & Ruijie Zhang. (2015) Prioritization of rheumatoid arthritis risk subpathways based on global immune subpathway interaction network and random walk strategy. Molecular BioSystems 11:11, pages 2986-2997.
Crossref
Tim E. Cawston, D.A. Young & Drew D. Rowan. 2015. Rheumatology. Rheumatology 152 159 .
Christopher J. Carbone & Serge Y. Fuchs. (2014) Eliminative Signaling by Janus Kinases: Role in the Downregulation of Associated Receptors. Journal of Cellular Biochemistry 115:1, pages 8-16.
Crossref
R. Fleischmann. (2013) Back to the future: oral small molecule kinases. Rheumatology 52:7, pages 1153-1154.
Crossref
Peter Hersey, Stuart Gallagher & Branka Mijatov. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer 143 155 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.